Business
PROCEPT BioRobotics Corp. Announces Investor Event at 2022 AUA Annual Meeting in New Orleans
REDWOOD CITY, Calif., April 11, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing
About this update from Procept Biorobotics Corporation
[{"type":"text","content":"REDWOOD CITY, Calif., April 11, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today it will host an in-person investor event on Friday, May 13, 2022 in New Orleans at the American Urology Association Annual Meeting from 8:30am to 10:00am Central Time. This meeting will include remarks from PROCEPT BioRobotics’ executive team, in addition to a surgeon panel on the benefits of its AquaBeam Robotic System. Members of PROCEPT BioRobotics’ management team presenting include: Reza Zadno – President & Chief Executive OfficerKevin Waters – Executive VP & Chief Financial OfficerSham Shiblaq – Executive VP & Chief Commercial OfficerBarry Templin – Senior VP, Clinical & Medical Affairs Clinical perspectives will also be provided by the following physicians: Dr. Pratik Desai, Board Certified Urologist at Potomac UrologyDr. Dean Elterman, Division of Urology, Toronto Western Hospital, University of TorontoDr. Brian Helfand, Division of Urology, NorthShore University Health System A live webcast of each event, as well as an archived recording, will be available on the “Investors” section of the company’s website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event About PROCEPT BioRobotics CorporationPROCEPT is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. PROCEPT has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 100 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy. Forward Loo...